ABCL
Price
$10.97
Change
+$0.62 (+5.99%)
Updated
Aug 13 closing price
Capitalization
3.37B
88 days until earnings call
Intraday BUY SELL Signals
VCYT
Price
$42.60
Change
-$2.08 (-4.66%)
Updated
Aug 13 closing price
Capitalization
3.42B
88 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

ABCL vs VCYT

ABCL vs VCYT Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
ABCL vs. VCYT commentary
Aug 14, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ABCL is a Buy and VCYT is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Aug 14, 2026
Stock price -- (ABCL: $10.97 vs. VCYT: $42.60)
Brand notoriety: ABCL and VCYT are both not notable
ABCL represents the Biotechnology, while VCYT is part of the Medical Specialties industry
Current volume relative to the 65-day Moving Average: ABCL: 177% vs. VCYT: 87%
Market capitalization -- ABCL: $3.37B vs. VCYT: $3.42B
ABCL [@Biotechnology] is valued at $3.37B. VCYT’s [@Medical Specialties] market capitalization is $3.42B. The market cap for tickers in the [@Biotechnology] industry ranges from $130.9B to $0. The market cap for tickers in the [@Medical Specialties] industry ranges from $3.82T to $0. The average market capitalization across the [@Biotechnology] industry is $2.23B. The average market capitalization across the [@Medical Specialties] industry is $17.81B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ABCL’s FA Score shows that 0 FA rating(s) are green whileVCYT’s FA Score has 0 green FA rating(s).

  • ABCL’s FA Score: 0 green, 5 red.
  • VCYT’s FA Score: 0 green, 5 red.
According to our system of comparison, VCYT is a better buy in the long-term than ABCL.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ABCL’s TA Score shows that 5 TA indicator(s) are bullish while VCYT’s TA Score has 4 bullish TA indicator(s).

  • ABCL’s TA Score: 5 bullish, 5 bearish.
  • VCYT’s TA Score: 4 bullish, 5 bearish.
According to our system of comparison, ABCL is a better buy in the short-term than VCYT.

Price Growth

ABCL (@Biotechnology) experienced а +67.99% price change this week, while VCYT (@Medical Specialties) price change was -7.69% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +1.08%. For the same industry, the average monthly price growth was -1.56%, and the average quarterly price growth was +3040.81%.

The average weekly price growth across all stocks in the @Medical Specialties industry was +0.61%. For the same industry, the average monthly price growth was +7.88%, and the average quarterly price growth was +24.02%.

Reported Earning Dates

ABCL is expected to report earnings on Nov 10, 2026.

VCYT is expected to report earnings on Nov 10, 2026.

Industries' Descriptions

@Biotechnology (+1.08% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

@Medical Specialties (+0.61% weekly)

Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
VCYT($3.43B) and ABCL($3.37B) have the same market capitalization . ABCL YTD gains are higher at: 220.760 vs. VCYT (1.188). VCYT has higher annual earnings (EBITDA): 137M vs. ABCL (-167.02M). ABCL (505M) and VCYT (485M) have equal amount of cash in the bank . VCYT has less debt than ABCL: VCYT (40.1M) vs ABCL (140M). VCYT has higher revenues than ABCL: VCYT (562M) vs ABCL (79.2M).
ABCLVCYTABCL / VCYT
Capitalization3.37B3.43B98%
EBITDA-167.02M137M-122%
Gain YTD220.7601.18818,588%
P/E RatioN/A30.43-
Revenue79.2M562M14%
Total Cash505M485M104%
Total Debt140M40.1M349%
FUNDAMENTALS RATINGS
VCYT: Fundamental Ratings
VCYT
OUTLOOK RATING
1..100
53
VALUATION
overvalued / fair valued / undervalued
1..100
54
Fair valued
PROFIT vs RISK RATING
1..100
91
SMR RATING
1..100
75
PRICE GROWTH RATING
1..100
50
P/E GROWTH RATING
1..100
98
SEASONALITY SCORE
1..100
50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
ABCLVCYT
RSI
ODDS (%)
Bearish Trend 1 day ago
90%
Bullish Trend 1 day ago
89%
Stochastic
ODDS (%)
Bearish Trend 1 day ago
90%
Bullish Trend 1 day ago
73%
Momentum
ODDS (%)
Bullish Trend 1 day ago
85%
Bearish Trend 1 day ago
73%
MACD
ODDS (%)
Bullish Trend 1 day ago
77%
N/A
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
80%
Bearish Trend 1 day ago
81%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
78%
Bearish Trend 1 day ago
85%
Advances
ODDS (%)
Bullish Trend 1 day ago
81%
Bullish Trend 16 days ago
73%
Declines
ODDS (%)
Bearish Trend 19 days ago
81%
Bearish Trend 1 day ago
79%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
81%
Bullish Trend 1 day ago
80%
Aroon
ODDS (%)
Bearish Trend 1 day ago
84%
Bearish Trend 1 day ago
90%
View a ticker or compare two or three
Interact to see
Advertisement
ABCL
Daily Signal:
Gain/Loss:
VCYT
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
FXED17.550.23
+1.33%
Sound Enhanced Fixed Income ETF
OND35.520.44
+1.25%
ProShares On-Demand ETF
GMAY44.030.10
+0.23%
FT Vest U.S. Eq Mod Buffr ETF - May
DEM54.770.10
+0.18%
WisdomTree Emerging Markets High Div ETF
FSML30.980.03
+0.10%
Franklin Small Cap Enhanced ETF

ABCL and

Correlation & Price change

A.I.dvisor indicates that over the last year, ABCL has been loosely correlated with RXRX. These tickers have moved in lockstep 59% of the time. This A.I.-generated data suggests there is some statistical probability that if ABCL jumps, then RXRX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ABCL
1D Price
Change %
ABCL100%
+5.94%
RXRX - ABCL
59%
Loosely correlated
+0.61%
VCYT - ABCL
56%
Loosely correlated
-4.66%
ABSI - ABCL
54%
Loosely correlated
-0.42%
CRSP - ABCL
52%
Loosely correlated
N/A
AXON - ABCL
51%
Loosely correlated
+2.64%
More

VCYT and

Correlation & Price change

A.I.dvisor indicates that over the last year, VCYT has been closely correlated with NTLA. These tickers have moved in lockstep 69% of the time. This A.I.-generated data suggests there is a high statistical probability that if VCYT jumps, then NTLA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To VCYT
1D Price
Change %
VCYT100%
-4.66%
NTLA - VCYT
69%
Closely correlated
-2.15%
VCEL - VCYT
60%
Loosely correlated
-0.42%
AXON - VCYT
58%
Loosely correlated
+2.64%
DNA - VCYT
57%
Loosely correlated
+0.42%
ABCL - VCYT
55%
Loosely correlated
+5.94%
More